The EPO published patent application EP3431603A1 for antisense molecules and methods for treating pathologies. The application, filed by the University of Western Australia, covers modified antisense oligonucleotides designed to target and treat specific disease-causing genetic sequences. The inventors named are Stephen Wilton, Sue Fletcher, Abbie Adams, and Penny Meloni. The publication date is March 25, 2026, and the application has been allocated IPC classifications C12N 15/113, A61K 31/7088, A61K 31/712, and A61P 21/00. The patent designates all standard EPO contracting states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

This publication establishes a priority date and makes the technical details of the antisense technology publicly available. The patent has not yet been granted and remains subject to EPO examination. Companies developing antisense-based therapeutics should review the published claims for potential overlap with their products or pipeline candidates. Freedom-to-operate analyses for antisense therapeutics targeting European markets should account for this published application. No compliance deadlines apply to this publication notice; however, third parties may file observations with the EPO during the examination phase.